ArticleMolecular and cellular biochemistry2016
The enzyme L-isoaspartyl (D-aspartyl) methyltransferase is required for VEGF-dependent endothelial cell migration and tubulogenesis.
Article in Molecular and cellular biochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 11 citations in OpenAlex.
- PCMT1 confirmed as a pan-cancer immune biomarker and a contributor to breast cancer metastasis.American journal of cancer research · 2024Article
- Article
- The Protein L-Isoaspartyl (D-Aspartyl) Methyltransferase Regulates Glial-to-Mesenchymal Transition and Migration Induced by TGF-β1 in Human U-87 MG Glioma Cells.International journal of molecular sciences · 2022Article
- PIMT Binding to C-Terminal Ala459 of CAIX Is Involved in Inside-Out Signaling Necessary for Its Catalytic Activity.International journal of molecular sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The protein L-isoaspartyl (D-aspartyl) methyltransferase (PIMT) methylates proteins carrying altered aspartyl residues in their structure. PIMT is postulated to limit the accumulation of these damaged proteins with abnormal aspartyl residues. However, little is known about the role of PIMT in tumor growth and almost nothing about its involvement in angiogenic processes. We previously reported that PIMT was up-regulated when endothelial cells were detached from extracellular matrix, leading us to postulate that PIMT could play a critical role during angiogenic steps, since the contacts between endothelial cells and the extracellular matrix are intensively regulated during this process. Here, we demonstrated that PIMT down-regulation by siRNA in human umbilical vein endothelial cells (HUVECs) inhibited both cell migration and tube formation in vitro when stimulated by vascular endothelial growth factor (VEGF). Conversely, overexpression of wild-type PIMT promoted HUVEC migration in the presence of VEGF, while this response was prevented in cells transfected with the inactive mutant PIMT(D83V). Similar results were obtained with the two forms of PIMT regarding their capacity to regulate the action of VEGF during the formation of capillary-like structures in vitro. Together, these data highlight the importance of the catalytic activity of PIMT to mediate VEGF effects during endothelial cell migration and tube formation in angiogenesis. Furthermore, these results identify a new function for PIMT as an enzyme involved in pro-angiogenic processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.